Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
Nvidia Pauses AI Cloud Financing Deals Amid Antitrust Concerns 
Toyota Global Sales Fall as China Demand Slumps 
Google Changes EU Spam Policy Amid Antitrust Scrutiny 
Aon Nears $17 Billion Deal to Buy USI Insurance From KKR 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
GM Plans C$1.1 Billion Canada Investment Amid U.S. Tariff Pressure 
Street Poller Media and The Boom of the Street Interview Ad Industry 
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’ 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
Add as a preferred source on Google
| Montrouge, April 3, 2018 |
DBV Technologies to Attend the 11th Kempen Life Sciences Conference
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced that Susanna Mesa, Chief Business Officer, will host investor meetings during the 11th Kempen Life Sciences Conference on Wednesday, April 18, 2018 at the Kempen & Co offices in Amsterdam, Netherlands.
About DBV Technologies
DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV's food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com
DBV Investor Relations Contact
Sara Blum Sherman
Senior Director, Investor Relations & Strategy
+1 212-271-0740
[email protected]
DBV Media Contact
Roberta Di Giorgio
Senior Director, Corporate Communications
+1 917-612-2861
[email protected]
Attachment:
http://www.globenewswire.com/NewsRoom/AttachmentNg/c85aa08f-22a4-4152-9093-3a2d4bc72c27
